Related Experiment Video
Updated: Sep 15, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Migraine management in Saudi Arabia: An expert consensus
Abdulrazaq S Albilali1, Ammar M Alkawi1, Naser D Alotaibi1
1From the Neurology Unit (Albilali), College of Medicine, King Saud Medical City, King Saud University, from Neuroscience Center (Alkawi, Alotaibi), King Faisal Specialist Hospital and Research Center, from the Neurology team (Qureshi), Speciality Medicine Department, John Hopkins Aramco Healthcare, Dhahran, from the Department of Neurology (Alabdali), College of Medicine, Imam Abdulrahman bin Faisal University, Dammam, from the Department of Neurology (Alabdaly), King Saud Medical City and King Salman Hospital, and from Imam Mohammed Ibn Saud University, Riyadh, from the Department of Neurology (Alenzi), King Fahad Specialist Hospital, Dammam, from the Department of Neurology (Al Khathaami, Alotaibi), King Abdulaziz Medical City, from the Ministry of National Guard-Health Affairs, From the Advanced Neuro-Musculoskeletal Care Center (Elchami), Samir Abbas Hospital, Jeddah, From the Department of Internal Medicine (Alesefir), College of Medicine, University of Hail, Hail, Kingdom of Saudi Arabia, and from Schwarzwald Klinik Neurology (Alabdaly), Bad Krozengin, Germany.
Expert consensus in Saudi Arabia recommends calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) as a first-line preventive treatment for migraine. This guidance aims to improve patient outcomes and reduce the burden of this neurological condition.
Area of Science:
- Neurology
- Pharmacology
Background:
- Migraine is a prevalent neurological disorder with significant impact on quality of life.
- Current treatment strategies require optimization for better patient outcomes.
Framework:
- Expert consensus established based on latest international guidelines and local clinical practice in Saudi Arabia.
- Focus on preventive treatment, specifically calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs).
Implementation:
- Recommendations cover treatment initiation criteria and patient selection for CGRP mAbs.
- Emphasis on early and effective intervention to manage migraine burden.
Implications:
- Integration of CGRP mAbs as a first-line therapy in Saudi Arabia.
- Enhancement of migraine care standards and addressing unmet needs in the local healthcare setting.
Related Concept Videos
Rheumatic Heart Disease III: Medical Management
Hypertension III: Clinical Manifestations and Diagnostic Studies
Aneurysm III: Interprofessional Care
Nephrotic Syndrome II : Assessment and Medical Management
Analgesia and Pain Management
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

